For many families, the most difficult parts of Alzheimer's care extend beyond memory loss. Watching someone become frightened, restless, or awake throughout the night can be just as difficult as the memory loss itself.
When these symptoms become harder to manage, some families begin exploring medical cannabis as a possible addition to a broader care plan.
Medical cannabis is not a cure for Alzheimer's disease, and current research does not show that it can stop, reverse, or slow the progression of the disease. Most research has focused on whether cannabinoids may influence certain symptoms that affect daily comfort and caregiver burden.
Alzheimer's disease is a progressive neurological condition that affects memory, thinking, behavior, and independence over time. As symptoms advance, many patients develop behavioral and physical challenges that become increasingly difficult for caregivers to manage.
Behavioral strategies, environmental modifications, caregiver education, and approved medications remain the foundation of Alzheimer's care. However, some patients continue to experience symptoms despite these approaches, leading researchers to investigate whether medical cannabis may have a role in symptom management.
Common symptoms include:
Because existing approaches may have limitations or side effects for some patients, researchers continue to investigate additional symptom-management approaches, including cannabinoids.
Cannabinoids interact with the body's endocannabinoid system, which researchers study for its potential role in processes related to sleep, appetite, mood, and nervous system function.
Researchers have observed changes in the endocannabinoid system in people living with Alzheimer's disease. Because cannabinoids such as THC and CBD interact with this system, they have become an area of ongoing research.
While scientists continue to study these interactions, current evidence supports investigation into symptom management rather than treatment of the underlying disease.
Research on medical cannabis for Alzheimer's remains limited, particularly in large, well-designed human clinical trials.
Much of the early research comes from laboratory and animal studies, where cannabinoids have been shown to influence inflammation and other biological processes associated with Alzheimer's disease. While these findings have generated scientific interest, they have not translated into proven clinical benefits in patients.
Human studies have primarily evaluated symptom management. Some small clinical studies and observational research suggest that certain cannabis-based products may help reduce agitation, improve sleep, stimulate appetite, or lessen anxiety in some individuals with Alzheimer's disease. However, the available evidence remains preliminary, and researchers have not identified which patients are most likely to benefit.
At this time, there is no evidence that medical cannabis improves memory, restores cognitive function, or slows the progression of Alzheimer's disease. Larger clinical trials are still needed.
Agitation is one of the most challenging symptoms for both patients and caregivers. Some studies have explored whether cannabinoid-based products may influence agitation-related symptoms in certain individuals, potentially making daily care more manageable.
Sleep disruption is common throughout the course of Alzheimer's disease. Some patients report changes in sleep patterns when using cannabis-based products, although controlled evidence remains limited.
Weight loss and poor appetite often become concerns as Alzheimer's progresses.THC has been studied in relation to appetite changes in certain medical contexts, although evidence specific to Alzheimer's disease remains limited.
Anxiety frequently contributes to restlessness, irritability, and sleep difficulties. Some cannabis-based products may promote a greater sense of calm in certain patients, although individual responses vary.
CBD for Alzheimer's patients has received considerable attention because it does not produce the intoxicating effects associated with THC.
Researchers are studying CBD for its potential anti-inflammatory and calming properties. Although much of the evidence remains preclinical, a physician may consider. Some clinicians may consider cannabinoid formulations with lower THC content when evaluating individual patient factors.
More research is needed to determine the role CBD may play in managing Alzheimer's-related symptoms.
Medical cannabis is not appropriate for every person living with Alzheimer's disease. Older adults are often more sensitive to cannabinoids, particularly THC.
Potential side effects include:
THC may also worsen short-term confusion, impair judgment, or increase disorientation in some patients with dementia, particularly at higher doses.
Drug interactions are another important consideration. Many people with Alzheimer's disease take multiple medications, and cannabinoids may affect how some of these medicines are processed by the body.
Because there are no standardized dosing guidelines for Alzheimer's disease, any use of medical cannabis should be individualized and occur under physician supervision.
For some families, medical cannabis may become one part of a broader symptom-management plan focused on comfort and quality of life.
The strongest evidence currently relates to managing symptoms such as agitation, sleep disturbances, appetite loss, and anxiety-not improving memory or slowing the progression of Alzheimer's disease.
Because older adults living with dementia are particularly vulnerable to side effects, any decision to use medical cannabis should be made carefully and in consultation with a licensed physician who can evaluate the patient's overall health, medications, and treatment goals.
If symptoms such as agitation, poor sleep, anxiety, or appetite loss remain difficult to manage, finding out whether you may qualify for medical cannabis through a licensed physician may be a reasonable next step.
No. Current research does not show that medical cannabis cures, prevents, or slows the progression of Alzheimer's disease. Most studies have focused on symptom management rather than disease modification.
Researchers are studying CBD because of its potential anti-inflammatory and calming properties. While early laboratory findings are encouraging, there is not enough clinical evidence to conclude that CBD improves memory or alters the course of Alzheimer's disease.
Yes. Some people with dementia may become more confused, dizzy, or disoriented after using THC, particularly at higher doses. Older adults are generally more sensitive to these effects, which is why physician supervision is important.
Medical cannabis is not approved as a treatment for Alzheimer's disease. Whether it may be appropriate depends on an individual's symptoms, overall health, and the medical cannabis laws in their state.
Doctors of Cannabis connects patients to licensed physicians through our telehealth partner network. You only pay if approved.
This article is authored by Dr. Erick Kaufman MD. Explore his other expert resources on medical cannabis.
Medical Marijuana for Alzheimer's: Benefits and Risks For many families, the...
Our team can help you understand the steps to get a medical cannabis card in your state.
